US Food and Drug Administration (FDA)

US Congress
#Investment #Politics #United States #US Food and Drug Administration (FDA)

After the midterms, biopharma needs more than a policy forecast

A Democratic Congress will likely sharpen oversight of the FDA and drug pricing, but the most consequential choices for drug developers in 2027 will still be made in clinical trial protocols, financing plans and portfolio reviews.  Washington has had a leadership change, but the development equation has not.  The November… Read More

#Exclusive Content #Opinion

Stamp of approval
#Phase II trial #Processa Pharmaceuticals #US Food and Drug Administration (FDA)

FDA clears Phase II study of VT-7208 in chronic spontaneous urticaria

The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for a Phase II study of Processa Pharmaceuticals’ VT-7208 in chronic spontaneous urticaria (CSU).  Processa is advancing VT-7208, a next-generation, CNS-penetrant, once-daily oral BTK inhibitor, across three Phase II proof-of-concept programmes, including CSU, food allergy… Read More

#News #Regulatory

Monoclonal antibodies
#Colorectal cancer #GSK #Immunotherapy #Monoclonal antibodies #Oncology #US Food and Drug Administration (FDA)

FDA approves first immunotherapy for advanced rectal cancer

The US Food and Drug Administration (FDA) has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly).  The approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer.  Patients with locally advanced rectal cancer often receive chemotherapy… Read More

#Cancer Research #News #Regulatory #Trending News

Neurons
#AC Immune #Immunotherapy #Neuroscience #Parkinson's #US Food and Drug Administration (FDA)

Immunotherapy for Parkinson’s gets FDA Fast Track Designation

AC Immune has received Fast Track designation and clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) for its anti-alpha-synuclein (a-syn) active immunotherapy candidate, ACI-7104, for the treatment of early-stage Parkinson’s disease (PD).  ACI-7104 is designed to induce a-syn-specific antibodies, preferentially recognising aggregated… Read More

#Editor's Choice #News #Regulatory

#Cardiomyopathy #Drug development #Drug discovery #FDA #HAYA Therapeutics #nHCM #RNA therapy #Symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) #US Food and Drug Administration (FDA)

Treatment underway for nonobstructive hypertrophic cardiomyopathy 

The US Food and Drug Administration (FDA) has granted Fast Track Designation for HAYA Therapeutics’ HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM).   The first-in-class investigational long non-coding RNA (lncRNA)-targeting therapy is in a Phase Ia/b trial, with the first cohort dosed this past May.  HTX-001 is a… Read More

#News